Help us fund research to slow, stop and reverse Parkinson’s
A research group in Cambridge - supported by The Cure Parkinson's Trust and Cambridge Centre for Parkinson-Plus - will be conducting a clinical trial to test whether suppressing the immune system can help to slow the progression of Parkinson's. Read more
We were thrilled to still be able to host the 2020 Tom Isaacs Charity Golf Day this year. Team members were invited to enjoy a round of golf in memory of The Cure Parkinson’s Trust’s late co-founder and President Tom Isaacs. Read more
Following the immense success last year’s Raid Pyrenean and this year’s virtual Raid Local event, we are excited to announce the Cure Parkinson’s 2021 Raid Series. Read more
The Cure Parkinson’s Trust are delighted to be the recipient of the 2020 Lloyd’s Market Charity Award receiving a £25,000 donation in support of our pioneering research into a cure for Parkinson’s. Read more
On 18 November, two of the city’s longest-standing fundraising events, the Gulls' Eggs and the Grouse & Grape Luncheons joined forces to deliver a brilliant virtual event raising £60,000 for The Cure Parkinson’s Trust’s ground-breaking research. Read more
Between 4 and 11 October, over 100 of our supporters embraced their favourite local routes and took part in The Cure Parkinson’s Trust’s (CPT) ‘Run Local’ event, - our first ever 7 day festival of running in support of our research. Read more
We are delighted to announce that TV writer, producer and comedian Paul Mayhew-Archer is now a patron of The Cure Parkinson’s Trust (CPT). Read more
In a recent study supported by The Cure Parkinson's Trust, researchers concluded that the elevated risk of Parkinson’s disease in patients with type 2 diabetes might be mitigated depending on the type of drugs prescribed to treat diabetes. Read more
In September, the annual International Linked Clinical Trials committee convened to prioritise drugs to direct through to clinical trial - over 20 world-leading Parkinson's experts reviewed a set of newly compiled drug dossiers with potential to treat Parkinson's. Read more
For the first time, this year's meeting for people with Parkinson's, was held online and focussed on the origins and development of Parkinson’s, including triggers, early symptoms and stages of the disease. Read more
In April the results of a major clinical trial - called the PASADENA study - were announced. Although the results indicated that the trial had not achieved a positive result based on a predetermined measure of success, the investigators conducting the study indicated that there were ‘signals of efficacy‘ in the data. Read more
The Cure Parkinson’s Trust (CPT) and Van Andel Institute (VAI) are delighted to welcome a third strategic funding partner, The John Black Charitable Foundation (JBCF), to the International Linked Clinical Trials (iLCT) programme. Together, these three have pledged USD $6.75 million to Parkinson’s research, over three years. Read more
This week the results of a large Cure Parkinson's Trust-funded clinical trial were released, evaluating the disease-modifying potential of the cholesterol-lowering drug simvastatin in people with Parkinson's. The results indicate that the treatment does not have any impact of the progression of the condition. Read more
On 5 September The Cure Parkinson’s Trust (CPT) launched the 3rd edition of Cure3, an acclaimed selling exhibition devised by Artwise Curators and kindly hosted by Bonhams, London, to raise funds and awareness of CPT’s research into a cure for Parkinson’s. Early results from Cure3 2020 confirm that this unique selling event has now raised over £1m for The Cure Parkinson’s Trust. Read more
Cure3 2020, the third edition of the acclaimed selling exhibition, is taking place this week in support of CPT. Read more
A corticosteroid medication used to reduce inflammation in conditions such as arthritis and asthma has shown to help COVID-19 patients - and there is a growing body of evidence to suggest that these medications may also be useful in the treatment of Parkinson's Read more
We are delighted to announce that the nominations for the 2020 Fundraiser of the Year Award are now open! Read more
In their epigenetics study of Parkinson's, researchers at the Van Andel Institute (Michigan) have identified a “master regulator” gene switch that may protect the brain from neurodegeneration. Read more
A research report published this week, highlights a protein that could represent the first 'biomarker' for Parkinson's progression. Read more
A collaborative deal between Denali and Biogen brings a new potential Parkinson's treatment a step closer. Read more
Supported by CPT, German Biotech company MODAG have announced positive results from their phase 1 clinical trial of Anle138b for Parkinson's. Read more
Recently published research, conducted by Parkinson's research advocates and CPT, presents an encouraging overview of current agents in the pipeline for the treatment of Parkinson's. This report represents one of the first classifications and in-depth analysis of its kind in the Parkinson's clinical trials arena Read more
As researchers in the field of Parkinson’s take steps to invite patients back to take part in face-to-face studies, we'd like to hear your views about returning to participate in research in the UK. Read more
CPT's Dr Richard Wyse is the co-editor of a recent Cochrane Report on GLP‐1 receptor agonists and their potential use in treating Parkinson's Disease Read more
Researchers in Israel have recently published an interesting new study which provides a novel insight and further independent support for simvastatin which CPT is clinically testing in people with Parkinson's. Read more
Long term supporters from the Leicestershire, Northamptonshire and Rutland Committee led by Meriel Buxton have produced and printed a wonderful magazine 'Cabbages and Kings' to help raise funds for CPT’s research. Read more
Research has shown that infusions of blood plasma from young animal models can improve the health of older animal models, and a recent study of plasma infusions in people with Parkinson's warrants further investigations. Read more
On Sunday 28 June, over 1000 supporters of The Cure Parkinson’s Trust (CPT) took to the saddle to take part in the charity’s “Raid Local” cycle challenge, and have - so far - raised an astonishing £250,000 (including gift aid) for CPT’s vital research into a cure for Parkinson’s. Read more
Recent research of large data in Sweden has shown removal of tonsils and appendixes reduces the risk of Parkinson's. Read more
A Chinese research group have shown that 'helper cells' in the brain called astrocytes can be converted to nerve cells, which then can go on to produce dopamine - the brain chemical lost in Parkinson's. This is exciting news, but further research is needed. Read more
Join CPT Patron Mike Tindall MBE and celebrity friends for the ‘Raid Local’ cycle challenge. Read more
A better knowledge of variations in our DNA could not only provide insights into the underlying biology of Parkinson's but could also help us understand why we are affected differently, and how best to treat the disease. Read more
The results of a phase l trial testing a potential vaccine for Parkinson's have been published. Using the body's own immune system to start developing antibodies (immunotherapy) this potential treatment targets a toxic protein called alpha-synuclein thought to be a contributing factor in Parkinson's. Read more
We are absolutely delighted to announce that our BBC Radio 4 Appeal, which aired on Sunday 12 April, has raised a staggering £104,060.75! We are humbled by the incredible generosity of all who donated in support of our vital research into a cure for Parkinson’s, particularly in these difficult times, and we would like to say a heartfelt thank you. Read more
For some considerable time CPT has been interested in nerve growth factors or 'neurotrophic' factors for Parkinson's. GDNF, CDNF and C-CDNF are three interesting candidates and our research work within this field continues with drive and urgency. Read more
Dr. Johnny Acheson is an Emergency Medical Consultant who is also living with Parkinson’s. Johnny has created sketches to fundraise and to educate about Parkinson’s and depict the humorous side of working in emergency medicine! Read more
CPT patron and Rugby World Cup winner Mike Tindall MBE organised a silent auction to support the three charities close to his heart, including The Cure Parkinson’s Trust. Read more
Dr Camille Carroll of Plymouth University, a member of our International Linked Clinical Trials (iLCT) committee, has led a group of researchers in exploring a platform for conducting Multi-Arm Multi-Stage clinical trials for Parkinson's. Read more
From Sunday the 26 April, supporters of The Cure Parkinson’s Trust came together to join the nationwide 2.6 Challenge, taking part in unique activities based around the number 2.6 or 26. Here we share some of the imaginative challenges our supporters took on. Read more
At present there is little or no research being undertaken on the impact of COVID-19 on the Parkinson's community. Now, Fox Insight has stepped up to the plate to facilitate this important emerging area of research. Read more
The results of the Phase lll STEADY-PD clinical trial have now been published. Read more
Statins are a well characterised class of medication that are used to lower cholesterol levels in the body. Evidence strongly suggests certain statins have been for use as a potential treatment for Parkinson's, this particularly applies to a statin called simvastatin Read more
Lower levels of dopamine are associated with the motor symptoms of the condition - slowness and rigidity of movement. New research, led by Prof. David Devos, proposes a continuous delivery of a more stable form of dopamine directly into the brain. Read more
We want to hear your stories, from the Parkinson’s community, about the creative ways you are keeping safe, motivated and upbeat at home during this time... Read more
Calling early career scientists! Feeling socially distanced? Maybe quarantined? Wondering what you can do to further your career during this time? How about presenting and discussing your research with other early career neuroscientists who are in the same boat! Read more
Many drugs developed for Parkinson's are targeted at specific genes, such as the GBA and the LRRK2 gene. To test whether these drugs work, we need to identify people with abnormalities in these genes who can be enrolled in clinical trials. Read more
Results of a disappointing clinical trial in 2013 testing a gene therapy for Parkinson's have been re-investigated with some new and important implications for future trials in the field. Read more
First and foremost in these difficult times we hope that everyone stays safe. This is an ongoing situation causing disruption and anxiety and CPT is monitoring and responding to the unprecedented COVID-19 crisis as it evolves. Read more
Most clinical trials involve a single therapy, being tested against a 'placebo' or control treatment for a fixed period of time. The MAMS study technique explores a potential new trial design for Parkinson's Read more
The Cure Parkinson's Trust is encouraged to see the growing field of study of exenatide in Parkinson's. Read more
CPT recently approved funding for Prof. Antony Cooper to find people with idiopathic Parkinson’s who could benefit from new therapies being developed for genetic forms of the condition, particularly GBA Parkinson's. Read more
On World Parkinson's Day we are partnering with Parkinson's UK to reach out to everyone affected by Parkinson's, in a joined up effort, to support a campaign of awareness to challenge misconceptions, and help people to better understand Parkinson's. Read more
In light of the recent outbreak of the novel coronavirus, we are closely monitoring government advice on the situation. Read more
The Krembil Knowledge Gaps in Parkinson's Disease Symposium addressed some of the fundamental questions for further advancing Parkinson's research. Read more
Herantis Pharma Plc have announced that their ongoing Phase 1-2 clinical trial testing the neuroprotective agent ‘cerebral dopamine neurotrophic factor’ (or CDNF) in people with Parkinson’s has met its primary endpoint Read more
The Cure Parkinson’s Trust (CPT) is delighted to have been chosen as one of Mercer and Hole’s 2020 charity partners. Read more
Recently published research from UCL suggests monitoring of levels of iron in people with Parkinson's may help with early diagnosis and earlier treatment of dementia Read more
Scientists in Australia have recently published pre-clinical research exploring multiple treatment approaches for Parkinson's, in particular using GDNF alongside cell replacement therapy. Read more
Recently, researchers in Minnesota (USA) published the results of a small pilot clinical trial investigating the safety of Ursodeoxycholic acid (or UDCA) in Parkinson's. Read more
Researchers at Sheffield and Oxford Universities have recently published research exploring 'subtypes' of Parkinson's in cell-culture studies, which has highlighted a drug that The Cure Parkinson's Trust is clinically testing. Read more
Two groups recently published independent journal articles suggesting that a genetic variation associated with Alzheimer's might also have an important influence in Parkinson's. Read more
This September, AEGIS London will be taking on the Castel Office2Office Ride, cycling from London to Amsterdam raising funds and awareness for The Cure Parkinson's Trust. Read more
In Parkinson’s there appears to be an over-abundance of inflammatory cells in the brain. This study will examine how azathioprine impacts this inflammation to determine whether this drug could be a future treatment for Parkinson's. Read more
At the forefront of treatments for diabetes is a class of drug called glucagon-like peptide 1 receptor (GLP-1R) agonists. There is now considerable evidence that suggest GLP-1R diabetes drugs could potentially be used in the treatment of Parkinson's. Read more
Scottish Michelin Star Chef Martin Wishart recently completed his incredible challenge of sailing 3,500 miles across the Atlantic, raising a phenomenal £69,000 for The Cure Parkinson’s Trust. Read more
The Cure Parkinson's Trust and the Van Andel Institute are delighted to be supporting two sub-studies led by Prof. Tom Foltynie within the important Bydureon phase lll trial... Read more
This June 46 supporters of The Cure Parkinson’s Trust (CPT) will be taking on the next extreme cycling challenge in the CPT Raid series: the legendary Raid Alpine. Read more
The Cure Parkinson's Trust (CPT) is delighted to announce the publication of the results of a Phase II clinical trial evaluating ambroxol as a potential treatment to slow the progression of Parkinson’s. Read more
As we reach this milestone, we reflect on what we have achieved since the charity began in 2005 and look ahead to the plans we are shaping to mark this anniversary... Read more
2019 was an exceptional year for The Cure Parkinson’s Trust, not only for raising further awareness of Parkinson’s but also for the breakthrough research we have supported. Find out more... Read more
Sir David Jones, Co-founder of The Cure Parkinson’s Trust (CPT), has died. Read more
Over 150 researchers attended this two-day conference focused on improving our understanding of the genetics of Parkinson's, sponsored by The Cure Parkinson's Trust. Read more
A drug, Anle138b, previously shown to rescue neurons in pre-clinical models of alpha synuclein-associated Parkinson's, is now being trialled in humans. Read more
Aligning Science Across Parkinson's (ASAP) was launched this year, with support from the Sergey Brin Family Foundation, and more recently ASAP announced the Global Parkinson's Genetics Program (GP2)... Read more
New research from Northwestern University in Chicago suggests that rather than being targeted towards individuals with LRRK2- or GBA-associated Parkinson's, novel therapies in these fields may be beneficial for others in the wider Parkinson's affected community. Read more
The US National Institute of Health (NIH) have recently announced the opening of a vast new data portal for Parkinson's research... Read more
A recently published study has identified a gene, DCLK1, as an important regulator of alpha synuclein in Parkinson's. Read more
A recent study of brain tissue finds certain genetic factors strongly associated with the incidence of Parkinson's and gives further validation to one of our Linked Clinical trials - the Ambroxol trial in people with Parkinson's... Read more
'The Parkinson’s Drug Trial: A Miracle Cure?' has won a Grierson Award for Best Science Documentary. The series aired in early 2019 and followed late CPT Co-founder Tom Isaacs and 8 other people through a pioneering drug delivery procedure... Read more
The Cure Parkinson's Trust is pleased to announce two new additions to its Research Committee: Dr Heather Mortiboys and Dr Kevin McFarthing. Read more
Presentations from our Autumn Research Patient Update Meeting are now available to view. Read more
To mark the 20th anniversary of running his Edinburgh restaurant, Scottish Michelin Star Chef Martin Wishart will be taking on the incredible challenge of sailing 3,500 miles across the Atlantic in a bid to raise awareness and funds for The Cure Parkinson’s Trust. Read more
Researchers in Dundee and Stanford (USA) have identified a novel method of reducing the hyperactivity of the gene mutation in LRRK2, a major cause of familial and sporadic cases of Parkinson's... Read more
The 2019 Tom Isaacs Charity Golf Day at Denham Golf Club saw 76 players enjoying a round of golf in memory of CPT’s late Co-founder and President, Tom Isaacs raising over £8,800 for CPT's pioneering Parkinson's research. Read more
The findings of this new study suggest that enhancing cellular GCase activity with a drug similar to the now being repurposed drug Ambroxol in Parkinson's, may be beneficial to both people with genetic variants of Parkinson's and those with no obvious genetic influence... Read more
The Milken Institute Center for Strategic Philanthropy and the Sergey Brin Family Foundation recently announced the launch of the Aligning Science Across Parkinson’s (ASAP) programme... Read more
Sun Pharma Advanced Research Company (SPARC) is conducting a Phase ll clinical trial (PROSEEK) to evaluate the safety and effectiveness of its experimental c-Abl inhibitor, K0706, in people with early Parkinson’s disease. Read more
Researchers at Stanford University in the US looking for new biomarkers of Parkinson's, recently identified a protein called MIRO that in initial data very accurately identifies people with the condition... Read more
The Cure Parkinson's Trust (CPT) is co-funding the ongoing PD-STAT clinical trial evaluating the disease modifying potential of the cholesterol lowering drug simvastatin in Parkinson's within our Linked Clinical Trials programme. The trial protocol has recently been published... Read more
The next phase of the Bydureon (exenatide-PD) clinical trial in Parkinson's has begun recruitment to determine, in a larger cohort, whether this diabetes treatment can slow down disease progression. Read more
The ninth annual Grouse & Grape Luncheon was held on Tuesday 8 October at the historic Spencer House, and attracted 300 guests who raised over £35,000 for The Cure Parkinson’s Trust. Read more
Researchers in Ottawa have announced a new discovery associated with the LRRK2 genetic form of Parkinson's... Read more
Voyager Therapeutics announced it is recruiting participants for the company’s Phase ll trial of the VY-AADC02 gene therapy for Parkinson’s, enrolling in US... Read more
This week, researchers at the Radboud University Medical Centre in Nijmegen (the Netherlands) published the results of a clinical trial evaluating an 'at home' high intensity exercise regime in people with Parkinson's, and they found that it had a positive effect. Read more
Chinese researchers in collaboration with scientists from the University of Iowa have today published new research suggesting that a drug, called Terazosin - which is used to treat enlarged prostates and high blood pressure - could be a useful drug to re-purpose for Parkinson's. Read more
Recently announced results from a clinical trial provide interesting support for a major theory about Parkinson's, and hope for individuals suffering from one of the common non-motor issues, constipation. Read more
In this study, Prof. Brundin and his team demonstrate the importance of microglia (the immune cells in the brain) to the transfer of the Parkinson's-associated protein alpha synuclein in the brain. They suggested that pharmacological regulation of neuroinflammation could represent a future therapy for Parkinson's... Read more
The 2019 international Linked Clinical Trials meeting was held at the end of August in Grand Rapids, Michigan - this annual event is an important date in our calendar and heralds the process by which we are bringing much needed novel therapies for the Parkinson's into clinical trial as quickly as possible... Read more
Researchers at UCL have recently published a study validating a mobile device test which could continually monitor individuals with Parkinson's... Read more
Bayer pharmaceutical has bought BlueRock Therapeutics which could have some important implications for the Parkinson's community... Read more